This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mahon, F. X. Articles by Reiffers, J. Search for Related Content PubMed PubMed Citation Articles by Mahon, F. X. Articles by Reiffers, J.

Follow-Up of Complete Cytogenetic Remission in Patients With Chronic Myeloid Leukemia After Cessation of Interferon Alfa

From the Service des Maladies du Sang, Centre Hospitalier Universitaire de Bordeaux, and Université Victor Segalen Bordeaux 2, Bordeaux; and Hôpital Haut-Levêque, Pessac, France.

Address reprint requests to J. Reiffers, MD, Université Victor Segalen, Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux, France; email: president{at}u-bordeaux2.fr

PURPOSE: A small proportion of patients with chronic myeloid leukemia (CML) achieve a complete cytogenetic response (CCR), defined as the disappearance of Philadelphia (Ph) chromosome–positive metaphases, after treatment with interferon alfa (IFN). In this population of patients, the question of whether treatment should then be withdrawn is not yet resolved.

PATIENTS AND METHODS: In the present study, we followed 15 patients who stopped IFN after achieving CCR. In nine patients IFN was stopped in view of adverse reactions (n = 8) or patient’s choice (n = 1). For the remaining six patients, the treatment was stopped because no BCR/ABL rearrangement could be detected by reverse transcriptase polymerase chain reaction (RT-PCR) in four successive analyses using peripheral-blood samples.

RESULTS: Loss of CCR and survival were not statistically different (P = .48; P = .7) for the 15 patients who stopped IFN compared with 41 other CCR patients who continued IFN therapy in our institution. The median follow-up after discontinuation of IFN treatment was 36 months (range, 6 to 108 months). Seven patients (47%) (females, or CCR > 24 months and RT-PCR negative before IFN cessation; P < .0001) did not relapse. Eight other patients (53%) relapsed (lost CCR) within 3 to 33 months of treatment discontinuation. One of them relapsed in major cytogenetic remission (MCR) and was still in MCR 87 months after stopping therapy without any treatment.

CONCLUSION: It is possible to stop IFN treatment at least in some patients with CML who achieve a prolonged period of CCR. This study also illustrates the hypothesis that persistence of low numbers of Ph-positive cells does not necessarily imply hematologic relapse.

This article has been cited by other articles:

				I. Rabhi-Essafi, A. Sadok, N. Khalaf, and D. M. Fathallah A strategy for high-level expression of soluble and functional human interferon {alpha} as a GST-fusion protein in E.coli Protein Eng. Des. Sel., May 1, 2007; 20(5): 201 - 209. [Abstract] [Full Text] [PDF]

				P. Rousselot, F. Huguet, D. Rea, L. Legros, J. M. Cayuela, O. Maarek, O. Blanchet, G. Marit, E. Gluckman, J. Reiffers, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Blood, January 1, 2007; 109(1): 58 - 60. [Abstract] [Full Text] [PDF]

				F.-X. Mahon, F. Huguet, G. Etienne, D. Rea, J.-M. Cayuela, G. Marit, M. Gardembas, J. Reiffers, and R. Philippe Imatinib Mesylate Discontinuation in Patients with Chronic Myelogenous Leukemia in Complete Molecular Remission: An Update Follow Up. Blood (ASH Annual Meeting Abstracts), November 1, 2006; 108(11): 2154 - 2154. [Abstract] [PDF]

				L. McCallum, S. Price, N. Planque, B. Perbal, A. Pierce, A. D. Whetton, and A. E. Irvine A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation Blood, September 1, 2006; 108(5): 1716 - 1723. [Abstract] [Full Text] [PDF]

				G. Martinelli, I. Iacobucci, G. Rosti, F. Pane, M. Amabile, F. Castagnetti, D. Cilloni, S. Soverini, N. Testoni, G. Specchia, et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients Ann. Onc., March 1, 2006; 17(3): 495 - 502. [Abstract] [Full Text] [PDF]

				H. Kantarjian, S. O'Brien, J. Cortes, F. Giles, J. Shan, M. B. Rios, S. Faderl, S. Verstovsek, G. Garcia-Manero, W. Wierda, et al. Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-{alpha} Failure and in Late CML-CP, Comparison with Historical Controls Clin. Cancer Res., January 1, 2004; 10(1): 68 - 75. [Abstract] [Full Text] [PDF]

				T. P. Hughes, J. Kaeda, S. Branford, Z. Rudzki, A. Hochhaus, M. L. Hensley, I. Gathmann, A. E. Bolton, I. C. van Hoomissen, J. M. Goldman, et al. Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia N. Engl. J. Med., October 9, 2003; 349(15): 1423 - 1432. [Abstract] [Full Text] [PDF]

				J. V. Melo, T. P. Hughes, and J. F. Apperley Chronic Myeloid Leukemia Hematology, January 1, 2003; 2003(1): 132 - 152. [Abstract] [Full Text] [PDF]